New Cholera Vaccine and Method for Conjugating Bacterial Polysaccharides to Proteins
Posted Jan 08 2012 7:00pm
Description of Invention: A new conjugate vaccine for cholera has been developed. The invention includes a new method to conjugate the O-specific polysaccharide-core part of the bacterial lipopolysaccharide and protein subcomponents. Conventional technology has entailed chemical treatment of both components to introduce linkers, which made them amenable for covalent linking. The new method simplifies production by utilizing squaric acid chemistry for conjugating the free amine-containing species (e.g. polysaccharides) directly to amine-containing species (e.g. proteins) without prior modification of either component. While demonstrated in this new cholera prototype vaccine, the technology is envisioned as generally applicable, thereby streamlining a complex production process.
Simplified production of conjugate vaccines
Advantages: The method in the present form is simple to perform, gives reproducible results, allows preparation of carbohydrate-protein constructs in a predictable way, and appears to be superior to protocols developed earlier.
Collaborative Research Opportunity: The National Institute of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize conjugate vaccines. For collaboration opportunities, please contact Marguerite J. Miller, M.B.A. at 301-496-9003 or email@example.com .
For Licensing Information Please Contact: Peter Soukas J.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 14, Rockville, MD 20852-3804 United States Email: firstname.lastname@example.org Phone: 301-435-4646 Fax: 301-402-0220